Some of previous comments were not addressed satisfy, specifically,

1) A solo section of Haemophilia Costs provided background information, and it should be integrated to the introduction section before the statement of study objective.

2) Table 1, is this just for drug cost? Then, the title should be revised.

3) It is unclear the patients selection criteria. What are selection and exclusion criteria? The paper stated “all patients included have received clotting factors during the study period”, does this mean that the patients without using factors were excluded from the study? Then, how can the costs represent hemophilia pateints?

4) Since the study period covered 3 years from 2011 to 2013, it is unclear how the costs were constructed, e.g. what time period to construct costs for each patients, 6 months or one year, or two years, or three years? It is unclear how the costs per year were calculated. If one patient have 3 years’ data, how to calculate the annual costs?

5) The methods section lacked of statistical analysis method. One-way ANOVAs or Student T-tests should be performed when analyses were performed for comparing age groups, haemophilia severity, and other comparison.

Level of interest: An article of limited interest

Quality of written English: Not suitable for publication unless extensively edited

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:
I declare that I have no competing interests